Jeffrey D Jacobs1, Thomas Wagner2, George Gulotta3, Chuanhong Liao4, Yan Chun Li5, Marc Bissonnette5, Joel Pekow6. 1. Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, WA, USA. 2. Department of Medicine, University of Chicago, Chicago, IL, USA. 3. Center for Research Informatics, University of Chicago, Chicago, IL, USA. 4. Department of Public Health Sciences, University of Chicago, Chicago, IL, USA. 5. Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, 900 East 57th St., MB #9, Chicago, IL, 60637, USA. 6. Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, 900 East 57th St., MB #9, Chicago, IL, 60637, USA. jpekow@bsd.uchicago.edu.
Abstract
BACKGROUND: Preclinical data demonstrate that activation of the renin-angiotensin system (RAS) contributes to mucosal inflammation, and RAS inhibition by angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) improves colitis in animal models. Less is known regarding the effects of RAS inhibition on clinical outcomes in inflammatory bowel disease (IBD) patients. AIM: Evaluate the impact of ACEI and ARB on clinical outcomes in IBD. METHODS: Rates of IBD-related hospitalizations, operations, and corticosteroid use were evaluated retrospectively in two groups. First, 111 IBD patients taking an ACEI or ARB were compared to nonusers matched 1:1 based on sex, age, diagnosis, disease location, and hypertension diagnosis. Second, outcomes in a cohort of 130 IBD patients were compared prior to and during ACEI/ARB exposure. RESULTS: Compared to matched controls, all IBD patients together with ACEI/ARB exposure had fewer hospitalizations (OR 0.26, p < 0.01), operations (OR 0.08, p = 0.02), and corticosteroid prescriptions (OR 0.5, p = 0.01). Comparing outcomes before and during ACEI/ARB use, there were no differences in hospitalizations, operations, or corticosteroid use for all IBD patients together, but patients with UC had increased hospitalizations (0.08 pre- vs. 0.16 during ACEI/ARB exposure, p = 0.03) and decreased corticosteroid use (0.24 pre-ACEI/ARB vs. 0.12 during ACEI/ARB exposure, p < 0.01) during ACEI/ARB use. CONCLUSIONS: IBD patients with ACEI/ARB exposure had fewer hospitalizations, operations, and corticosteroid use compared to matched controls. No differences in outcomes were observed in individuals on ACEI/ARB therapy when compared to a period of time prior to medication exposure.
BACKGROUND: Preclinical data demonstrate that activation of the renin-angiotensin system (RAS) contributes to mucosal inflammation, and RAS inhibition by angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) improves colitis in animal models. Less is known regarding the effects of RAS inhibition on clinical outcomes in inflammatory bowel disease (IBD) patients. AIM: Evaluate the impact of ACEI and ARB on clinical outcomes in IBD. METHODS: Rates of IBD-related hospitalizations, operations, and corticosteroid use were evaluated retrospectively in two groups. First, 111 IBD patients taking an ACEI or ARB were compared to nonusers matched 1:1 based on sex, age, diagnosis, disease location, and hypertension diagnosis. Second, outcomes in a cohort of 130 IBD patients were compared prior to and during ACEI/ARB exposure. RESULTS: Compared to matched controls, all IBD patients together with ACEI/ARB exposure had fewer hospitalizations (OR 0.26, p < 0.01), operations (OR 0.08, p = 0.02), and corticosteroid prescriptions (OR 0.5, p = 0.01). Comparing outcomes before and during ACEI/ARB use, there were no differences in hospitalizations, operations, or corticosteroid use for all IBD patients together, but patients with UC had increased hospitalizations (0.08 pre- vs. 0.16 during ACEI/ARB exposure, p = 0.03) and decreased corticosteroid use (0.24 pre-ACEI/ARB vs. 0.12 during ACEI/ARB exposure, p < 0.01) during ACEI/ARB use. CONCLUSIONS: IBD patients with ACEI/ARB exposure had fewer hospitalizations, operations, and corticosteroid use compared to matched controls. No differences in outcomes were observed in individuals on ACEI/ARB therapy when compared to a period of time prior to medication exposure.
Authors: R Jaszewski; V Tolia; M N Ehrinpreis; J H Bodzin; R R Peleman; R Korlipara; J V Weinstock Journal: Gastroenterology Date: 1990-06 Impact factor: 22.682
Authors: M Fukuzawa; J Satoh; M Sagara; G Muto; Y Muto; S Nishimura; S Miyaguchi; X L Qiang; Y Sakata; T Nakazawa; F Ikehata; S Ohta; T Toyota Journal: Immunopharmacology Date: 1997-04
Authors: Manabu Okawada; Hiroyuki Koga; Scott D Larsen; Hollis D Showalter; Anjanette J Turbiak; Xiaohong Jin; Peter C Lucas; Elke Lipka; John Hillfinger; Jae Seung Kim; Daniel H Teitelbaum Journal: Dig Dis Sci Date: 2011-03-12 Impact factor: 3.199
Authors: John J Byrnes; Stefan Gross; Courtney Ellard; Kelly Connolly; Stephen Donahue; Dominic Picarella Journal: Inflamm Res Date: 2009-06-11 Impact factor: 4.575
Authors: Lei He; Jie Du; Yinyin Chen; Chunyan Liu; Min Zhou; Sarbani Adhikari; David T Rubin; Joel Pekow; Yan Chun Li Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-04-17 Impact factor: 4.052
Authors: Ahmed M Kabel; Aliaa Atef; Hany M Borg; Azza A K El-Sheikh; Hana J Al Khabbaz; Hany H Arab; Remon S Estfanous Journal: Pharmaceuticals (Basel) Date: 2022-05-13
Authors: Genevieve L Y Rocheleau; Terry Lee; Yassene Mohammed; David Goodlett; Kevin Burns; Matthew P Cheng; Karen Tran; David Sweet; John Marshall; Arthur S Slutsky; Srinivas Murthy; Joel Singer; David M Patrick; Bin Du; Zhiyong Peng; Todd C Lee; John H Boyd; Keith R Walley; Francois Lamontagne; Robert Fowler; Brent W Winston; Greg Haljan; Donald C Vinh; Alison McGeer; David Maslove; Santiago Perez Patrigeon; Puneet Mann; Kathryn Donohoe; Geraldine Hernandez; James A Russell Journal: Crit Care Med Date: 2022-05-18 Impact factor: 9.296